HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WR 242511

RN given refers to parent cpd

Also Known As:

WR 242511, phosphate (1:2) salt; WR-242511; WR242511

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Aminoquinolines: 29
        Primaquine: 1165
        WR 242511: 4

Experts

1.	Armstrong, Kevin: 1 article (09/2008)
2.	Baskin, Steven: 1 article (09/2008)
3.	Briscoe, Crystal: 1 article (09/2008)
4.	Duniho, Steven: 1 article (09/2008)
5.	Gold, Mark: 1 article (09/2008)
6.	Kahler, David: 1 article (09/2008)
7.	Moran, Anita: 1 article (09/2008)
8.	Rockwood, Gary: 1 article (09/2008)

Related Diseases

1.	Methemoglobinemia 09/01/2008 - "The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey. "
2.	Poisoning 09/01/2008 - "It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity."
3.	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 02/01/1991 - "In rat therapy models, the WRAIR compounds affected Pneumocystis pneumonia at doses as low as 0.25 mg/kg (WR242511) or 0.5 mg/kg (WR6026 and WR238605). "
4.	Malaria 07/02/1993 - "WR 242511 (or I) is a new compound of the 8-aminoquinoline class designed to replace primaquine for the treatment of malaria. "
5.	Hemoglobinuria 09/01/2008 - "Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose. "

Related Drugs and Biologics

1.	Primaquine
2.	8-aminoquinoline
3.	tafenoquine
4.	floxacrine
5.	menoctone

Related Therapies and Procedures

1.	Therapeutics